Optimal Management Strategies for Chronic Iron Overload
- 1 January 2007
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 67 (5) , 685-700
- https://doi.org/10.2165/00003495-200767050-00004
Abstract
Iron overload is characterised by excessive iron deposition and consequent injury and dysfunction of target organs, especially the heart, liver, anterior pituitary, pancreas and joints. Iron overload disorders are common worldwide and occur in most major race/ethnicity groups. Physiological mechanisms to excrete iron are very limited. Thus, all patients with iron overload need safe and effective treatment that is compatible with their co-existing medical conditions. Treatments for iron overload include phlebotomy and erythrocytapheresis that remove iron predominantly as haemoglobin, and chelation therapy with drugs that bind excess iron selectively and increase its excretion. The most important potential benefits of therapy are preventing deaths due to cardiac siderosis and hepatic cirrhosis. Preventing iron-related injury to endocrine organs is critical in children. Successful treatment or prevention of iron overload increases quality of life and survival in many patients. This article characterises the major categories of iron overload disorders, tabulates methods to evaluate and treat iron overload, and describes treatment options for iron overload disorders. Research needed to advance knowledge about treatment of iron overload is proposed.Keywords
This publication has 142 references indexed in Scilit:
- Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final resultsBlood, 2006
- Future Chelation Monotherapy and Combination Therapy Strategies in Thalassemia and Other Conditions. Comparison of Deferiprone, Deferoxamine, ICL670, GT56-252, L1NAll and Starch Deferoxamine PolymersHemoglobin, 2006
- Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1α that augments transcriptional activity of CCAAT/enhancer-binding protein-αLeukemia, 2005
- Treatment of Iron Overload in the “Ex‐Thalassemic”: Report from the Phlebotomy ProgramaAnnals of the New York Academy of Sciences, 1998
- Evaluation of a new method of administration of the iron chelating agent deferoxamineThe Journal of Pediatrics, 1997
- What is Ineffective Erythropoiesis in Myelodysplastic Syndromes?Leukemia & Lymphoma, 1995
- Agranulocytosis and thrombocytopenia, Blackfan-Diamond anaemia, and oral chelationThe Lancet, 1990
- Clinical Consequences of Acquired Transfusional Iron Overload in AdultsNew England Journal of Medicine, 1981
- Iron Absorption in the Thalassemia Syndromes and Its Inhibition by TeaNew England Journal of Medicine, 1979
- Excretion of iron in response to deferoxamine in sickle cell anemiaThe Journal of Pediatrics, 1978